My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

Nuvalent, Inc. - Class A Common Stock (NQ:NUVL)

94.65 -0.03 (-0.03%)

Streaming Delayed Price Updated: 10:09 AM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Nuvalent, Inc. - Class A Common Stock

< Previous 1 2 3 Next >

This Waste Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

November 12, 2025

Via Benzinga

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

This Thermo Fisher Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

August 19, 2025

Via Benzinga

Nuvalent (NUVL) Q2 R&D Up 65% ↗

August 07, 2025

Via The Motley Fool

Nuvalent Inc-A (NASDAQ:NUVL) Reports Q2 2025 Earnings Miss with Focus on Oncology Pipeline Progress ↗

August 07, 2025

Nuvalent (NUVL) reported Q2 2025 EPS of -$1.31, slightly missing estimates, with no revenue as expected. Shares rose pre-market as investors focus on its oncology pipeline, including zidesamtinib's NDA...

Via Chartmill

Topics Earnings

Why Nuvalent (NUVL) Shares Are Down 6% Today ↗

September 17, 2024

Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each.

Via Benzinga

NUVL Stock Earnings: Nuvalent Misses EPS for Q2 2024 ↗

August 08, 2024

NUVL stock results show that Nuvalent missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

NUVL Stock Earnings: Nuvalent Misses EPS for Q1 2024 ↗

May 09, 2024

NUVL stock results show that Nuvalent missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Nuvalent Touts 'Positive' Data From Zidesamtinib Trial For Pretreated Patients With Advanced Form Of Lung Cancer ↗

June 24, 2025

Nuvalent releases pivotal ARROS-1 trial data and plans to begin a rolling NDA submission for zidesamtinib in July 2025.

Via Benzinga

This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday ↗

December 30, 2024

Via Benzinga

This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

December 30, 2024

Via Benzinga

From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update

October 28, 2024

The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B).

Via News Direct

Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗

September 22, 2024

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week.

Via Benzinga

Topics Economy

Recap: Nuvalent Q4 Earnings ↗

February 27, 2024

Via Benzinga

Recap: Nuvalent Q3 Earnings ↗

November 14, 2023

Via Benzinga

Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity ↗

September 16, 2024

Nuvalent presented updated Phase 1 data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024. Key data showed promising response rates in pretreated patients, with pivotal results expected in...

Via Benzinga

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths ↗

September 16, 2024

Nuvalent and Iteos delivered promising updates in their lung cancer studies. But three patients died in one test.

Via Investor's Business Daily

Topics Death

Crude Oil Surges Over 1%; Instil Bio Shares Plunge ↗

September 16, 2024

Via Benzinga

Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday ↗

September 16, 2024

Via Benzinga

Lucid, Grifols And Amer Sports Are Among Top 8 Mid Cap Stock Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio? ↗

August 25, 2024

Via Benzinga

Where Nuvalent Stands With Analysts ↗

October 05, 2023

Via Benzinga

Why Nuvalent Stock Was Soaring Wednesday ↗

October 04, 2023

The company reported preliminary data on a non-small cell lung cancer therapy.

Via The Motley Fool

3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally ↗

June 24, 2024

Although short-squeeze stocks to buy present great risk, betting against the bears can also yield dramatically robust returns.

Via InvestorPlace

Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio? ↗

June 09, 2024

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.

Via Benzinga

7 Biotech Stocks to Get In Now Before Investors Catch On ↗

October 23, 2023

Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.

Via InvestorPlace

Why Nuvalent Stock Tanked on Tuesday ↗

October 17, 2023

The dilution monster stalked the company following the announcement of a new capital-raising effort.

Via The Motley Fool

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet ↗

October 06, 2023

Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance...

Via Benzinga

Why Nuvalent Stock Skyrocketed 35% This Week ↗

October 05, 2023

Nuvalent announced favorable preliminary data in a clinical trial for its lung cancer drug. Here's what investors need to know.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 04, 2023

Via Benzinga

Challenging Road Ahead for Cancer Drugs, Nuvalent Seeks to Break the Mold ↗

September 27, 2023

Stifel initiated coverage on Nuvalent Inc (NASDAQ: NUVL), recognizing that adopting a bullish stance in anticipation of Phase 1 cancer drug data, mainly when derived from heavily pretreated patients,...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition